Impact of Doxorubicin-Based Chemotherapy on Renal Function: Assessing the Acute Kidney Injury by Changes in Serum Creatinine and Nephrotoxicity

Barbosa, R. R., Bourguignon, T. B., Torres, L. D., Arruda, L. S., Jacques, T. de M., Serpa, R. G., Calil, O. de A., & Barbosa, L. F. M. (2018). Anthracycline-associated cardiotoxicity in adults: systematic review on the cardioprotective role of beta-blockers. Revista Da Associação Médica Brasileira, 64(8), 745–754. https://doi.org/10.1590/1806-9282.64.08.745

Chen, C., Xie, D., Gewirtz, D. A., & Li, N. (2022). Nephrotoxicity in cancer treatment: An update. Advances in Cancer Research, 155, 77–129. https://doi.org/10.1016/BS.ACR.2022.03.005

Chen, W., Liu, I., Tomiyasu, H., Lee, J., Cheng, C., Liao, A. T., Liu, B., Liu, C., & Lin, C. (2019). Imatinib enhances the anti-tumour effect of doxorubicin in canine B-cell lymphoma cell line. The Veterinary Journal, 254, 105398. https://doi.org/10.1016/j.tvjl.2019.105398

Chiruvella, V., Annamaraju, P., & Guddati, A. K. (2020). Management of nephrotoxicity of chemotherapy and targeted agents: 2020. American Journal of Cancer Research, 10(12), 4151–4164.

Drozdzik, M., Drozdzik, M., & Oswald, S. (2021). Membrane Carriers and Transporters in Kidney Physiology and Disease. Biomedicines, 9(4), 426. https://doi.org/10.3390/biomedicines9040426

Gounden, V., Bhatt, H., & Jialal, I. (2024). Renal Function Tests.

Ingrasciotta, Y., Sultana, J., Giorgianni, F., Caputi, A. P., Arcoraci, V., Tari, D. U., Linguiti, C., Perrotta, M., Nucita, A., Pellegrini, F., Fontana, A., Cavagna, L., Santoro, D., & Trifirò, G. (2014). The Burden of Nephrotoxic Drug Prescriptions in Patients with Chronic Kidney Disease: A Retrospective Population-Based Study in Southern Italy. PLoS ONE, 9(2), e89072. https://doi.org/10.1371/journal.pone.0089072

Johnson, M., & Keyes, D. (2024). Anthracycline Toxicity.

Jurczak, W., Długosz-Danecka, M., & Szmit, S. (2020). Cardio-oncology for better lymphoma therapy outcomes. The Lancet Haematology, 7(4), e273–e275. https://doi.org/10.1016/S2352-3026(20)30066-1

Knights, K. M., Rowland, A., & Miners, J. O. (2013). Renal drug metabolism in humans: the potential for drug–endobiotic interactions involving cytochrome P450 (CYP) and UDP ‐glucuronosyltransferase (UGT). British Journal of Clinical Pharmacology, 76(4), 587–602. https://doi.org/10.1111/bcp.12086

Kwon, Y. (2021). Possible Beneficial Effects of N-Acetylcysteine for Treatment of Triple-Negative Breast Cancer. Antioxidants, 10(2), 169. https://doi.org/10.3390/antiox10020169

Lyrio, R. M. da C., Rocha, B. R. A., Corrêa, A. L. R. M., Mascarenhas, M. G. S., Santos, F. L., Maia, R. da H., Segundo, L. B., de Almeida, P. A. A., Moreira, C. M. O., & Sassi, R. H. (2024). Chemotherapy-induced acute kidney injury: epidemiology, pathophysiology, and therapeutic approaches. Frontiers in Nephrology, 4. https://doi.org/10.3389/fneph.2024.1436896

Marinello, J., Delcuratolo, M., & Capranico, G. (2018). Anthracyclines as Topoisomerase II Poisons: From Early Studies to New Perspectives. International Journal of Molecular Sciences, 19(11), 3480. https://doi.org/10.3390/ijms19113480

McGowan, J. V, Chung, R., Maulik, A., Piotrowska, I., Walker, J. M., & Yellon, D. M. (2017). Anthracycline Chemotherapy and Cardiotoxicity. Cardiovascular Drugs and Therapy, 31(1), 63–75. https://doi.org/10.1007/s10557-016-6711-0

Mukai, H., Kogawa, T., Matsubara, N., Naito, Y., Sasaki, M., & Hosono, A. (2017). A first-in-human Phase 1 study of epirubicin-conjugated polymer micelles (K-912/NC-6300) in patients with advanced or recurrent solid tumors. Investigational New Drugs, 35(3), 307–314. https://doi.org/10.1007/s10637-016-0422-z

Perazella, M. A. (2018). Pharmacology behind Common Drug Nephrotoxicities. Clinical Journal of the American Society of Nephrology, 13(12), 1897–1908. https://doi.org/10.2215/CJN.00150118

Perazella, M. A., & Izzedine, H. (2015). New drug toxicities in the onco-nephrology world. Kidney International, 87(5), 909–917. https://doi.org/10.1038/ki.2015.30

Rosner, M. H., & Perazella, M. A. (2017). Acute Kidney Injury in Patients with Cancer. New England Journal of Medicine, 376(18), 1770–1781. https://doi.org/10.1056/NEJMra1613984

Santos, M. L. C., Brito, B. B. de, Silva, F. A. F. da, Botelho, A. C. dos S., & Melo, F. F. de. (2020). Nephrotoxicity in cancer treatment: An overview. World Journal of Clinical Oncology, 11(4), 190–204. https://doi.org/10.5306/wjco.v11.i4.190

Savani, M., & Skubitz, K. M. (2019). Long-term Outcome After Doxorubicin and Ifosfamide Overdose in a Patient With Osteosarcoma and BARD1 Mutation. Journal of Pediatric Hematology/Oncology, 41(2), e94–e96. https://doi.org/10.1097/MPH.0000000000001264

Wu, Q., Li, W., Zhao, J., Sun, W., Yang, Q., Chen, C., Xia, P., Zhu, J., Zhou, Y., Huang, G., Yong, C., Zheng, M., Zhou, E., & Gao, K. (2021). Apigenin ameliorates doxorubicin-induced renal injury via inhibition of oxidative stress and inflammation. Biomedicine & Pharmacotherapy, 137, 111308. https://doi.org/10.1016/j.biopha.2021.111308

Yang, Y., Li, H., Zhou, Q., Peng, Z., An, X., Li, W., Xiong, L., Yu, X., Jiang, W., & Mao, H. (2016). Renal Function and All-Cause Mortality Risk Among Cancer Patients. Medicine, 95(20), e3728. https://doi.org/10.1097/MD.0000000000003728

Yemm, K. E., Alwan, L. M., Malik, A. B., & Salazar, L. G. (2019). Renal toxicity with liposomal doxorubicin in metastatic breast cancer. Journal of Oncology Pharmacy Practice, 25(7), 1738–1742. https://doi.org/10.1177/1078155218798157